Sumamigren, pills 50mg, 6pcs

Composition

Pharmacological action

Pharmacological action – serotonergic, anti-migraine.

Sumatriptan is a specific selective agonist of vascular 5-hydroxytryptamine-1 receptors (5HT_1D), does not affect other subtypes of 5 HT-serotonin receptors (5 HT_2-5HT₇).

5HT_{-1D receptors} are located mainly in the blood vessels of the brain, and their stimulation leads to narrowing of these vessels. Reduces the sensitivity of the trigeminal nerve. Both of these effects may underlie the antimigrenous effect of sumatriptan. The clinical effect is usually noted 30 minutes after ingestion of the drug.

Pharmacokinetics

After oral use, sumatriptan is rapidly absorbed,70% of the_cmax is reached in 45 minutes. After taking 100 mg_{, cmax} in blood plasma averages 54 ng / ml. Bioavailability is 14% due to intensive presystemic metabolism and incomplete absorption. Binding to plasma proteins is low (14-21%).

Sumatriptan is metabolized by MAO A. The main metabolite, the indoleacetic analog of sumatriptan, is mainly excreted in the urine as a free acid and a glucuronide conjugate. This metabolite has no activity against 5HT1-and₅HT2-serotonin receptors. Migraine attacks do not appear to have a significant effect on the pharmacokinetics of sumatriptan taken orally.

Indications

Relief of migraine attacks with or without aura.

Use during pregnancy and lactation

The use of sumatriptan is contraindicated in pregnancy.

Breast-feeding should be discontinued for the duration of treatment. In the case of taking the drug, breastfeeding is possible no earlier than in 24 hours.

Use in children

Contraindication: patients under 18 years of age.

Contraindications

• individual powinna sensitivity to any component Sumamigren;
• hemiplegic, basilar and oftalmologicheskiy form of migraine;
• coronary artery disease (including myocardial infarction, myocardial infarction, Prinzmetal’s angina), as well as the presence of symptoms suggesting the presence of coronary artery disease;
• occlusive peripheral vascular disease;
• stroke or transient ischemic attack (including in the anamnesis);
• uncontrolled hypertension;
• concomitant use with ergotamine or its derivatives (including metanephric);
• application in patients receiving MAO inhibitors or earlier than 2 weeks after their removal;
• severe disturbances of liver function and/or kidney disease;
• age under 18 and over 65 years of age (safety and efficacy have not been established);
• pregnancy and lactation.

Side effects

On the part of the body in celombol, sensations of heat, tingling, a feeling of compression or heaviness (usually transient, but can be intense and occur in various parts of the body, including in the chest or throat); hot flashes, Dizziness, a feeling of weakness, fatigue, drowsiness (usually mild or moderate, are transient) are also possible. From the cardiovascular system: decreased blood pressure, bradycardia, tachycardia, transient increase in blood pressure; rarely-rhythm disturbances, transient ECG changes of ischemic type, coronary artery spasm, myocardial infarction; in isolated cases-Raynaud’s syndrome. From the digestive system: nausea, vomiting, ischemic colitis (the connection of these phenomena with taking sumatriptan is not precisely established); abdominal discomfort, Dysphagia, increased activity of hepatic transaminases. From the central nervous system, dizziness; rarely-seizures (in some cases observed in patients with a history of seizures or in conditions predisposing to the development of seizures); sometimes – diplopia, scotoma, nystagmus, decreased visual acuity; extremely rarely – partial transient loss of vision (please note that visual disturbances may be associated with a migraine attack). Allergic reactions rash, pruritus, erythema, urticaria; in isolated cases-anaphylactic reactions.

Interaction

No drug interactions were observed between sumatriptan and propranolol, flunarizine, pisotifen, and ethanol.

Prolonged vasospasm was observed when taking ergotamine concomitantly. Sumatriptan can be prescribed no earlier than 24 hours after taking drugs containing ergotamine, and drugs containing ergotamine can be prescribed no earlier than 6 hours after taking sumatriptan.

Concomitant use of sumatriptan and an MAO inhibitor is contraindicated, since interaction between them is possible.

There are very rare reports from post-marketing surveillance of the development of serotonin syndrome (including psychiatric disorders, autonomic lability and neuromuscular disorders) as a result of concomitant use of SSRIs and sumatriptan. Serotonin syndrome has also been reported when triptans are co-administered with SSRIs.

How to take, course of use and dosage

Tablets are taken orally whole, washed down with water.

The recommended single dose is 50 mg (1 tab. ), in some cases it may be necessary to use the drug in a higher dose of 100 mg. If the symptoms of migraine do not disappear or decrease after taking the first dose, then the drug should not be prescribed again to stop the ongoing attack. The drug can be used to stop subsequent migraine attacks.

If symptoms have subsided or subsided and then resumed, you can take a second dose within the next 24 hours. The maximum dose of the drug is 300 mg for 24 hours.

Overdose

In case of overdose, the patient should be monitored for 10 hours, carrying out symptomatic therapy as necessary.

There are no data on the effect of hemodialysis or peritoneal dialysis on the plasma concentration of sumatriptan.

Special instructions

Sumatriptan should only be prescribed if the diagnosis of migraine is not in doubt, and it should be used as early as possible after the onset of a migraine attack, although it is equally effective when used at any stage of the attack.

The drug should not be used for preventive purposes.

Sumatriptan should be used with caution in patients with controlled arterial hypertension; diseases in which the absorption, metabolism or excretion of the drug may change (for example, impaired renal or liver function).

There are very rare reports from post-marketing surveillance of the development of serotonin syndrome (including psychiatric disorders, autonomic lability and neuromuscular disorders) as a result of concomitant use of selective serotonin reuptake inhibitors (SSRIs) and sumatriptan. Serotonin syndrome has also been reported when triptans are co-administered with selective serotonin and norepinephrine reuptake inhibitors (SSRIs). In the case of concomitant use with drugs from the SSRI/SSRI group, the patient’s condition should be carefully monitored.

Sumatriptan should be taken with caution in patients with epilepsy and any conditions with a reduced threshold of convulsive readiness.

Concomitant use of other triptans/5-HT1 agonists with sumatriptan is not recommended.

In patients with hypersensitivity to sulfonamides, the use of sumatriptan may cause allergic reactions, the severity of which varies from skin manifestations to anaphylaxis. Data on cross-sensitivity are limited, but caution should be exercised when prescribing sumatriptan to such patients.

As with other anti-migraine medications, other potentially serious neurological conditions should be excluded when sumatriptan is prescribed in patients with previously undiagnosed migraines or in patients with atypical migraines. It should be noted that patients with migraines have an increased risk of developing certain cerebrovascular complications (stroke or transient cerebrovascular accident).

Sumatriptan should not be administered to patients with suspected heart disease without a preliminary examination to rule out cardiovascular disease. These patients include postmenopausal women, men over the age of 40, and patients with risk factors for CHD. Although the examination does not always detect heart disease in some patients, in very rare cases they develop side effects from the cardiovascular system. After taking sumatriptan, there may be transient intense pain and tightness in the chest, extending to the neck area.If there is reason to believe that these symptoms are a manifestation of CHD, it is necessary to conduct an appropriate diagnostic examination.

The abuse of medications intended for the relief of migraine attacks is associated with increased headaches in sensitive patients (headache associated with drug abuse). However, discontinuation of the drug should be considered.

Do not exceed the recommended dose of sumatriptan.

Influence on the ability to drive motor vehicles and manage mechanisms

Patients with migraines may experience drowsiness associated with both the disease itself and taking sumatriptan, so they should be especially careful when driving a car and working with moving mechanisms.

Form of production

Sumamigren. Film-coated tablets.

Storage conditions

The drug should be stored out of the reach of children at a temperature not exceeding 25°C.

Shelf

life is 5 years.

Active ingredient

Sumatriptan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets